Igzelym

Ticagrelor, the active ingredient in Igzelym, is a P2Y12 receptor antagonist presented as an oral formulation for systemic use. It reduces platelet aggregation and is indicated for patients with acute coronary syndrome, myocardial infarction prevention, and as part of post‑percutaneous coronary intervention antiplatelet therapy.

GNH USA supplies Igzelym as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured manufacturing and distribution networks that meet European Union standards. Our team ensures regulatory compliance and reliable delivery across multiple continents.

Ticagrelor is an antiplatelet agent that targets the P2Y12 ADP receptor pathway in cardiovascular disease. - Acute coronary syndrome: reduces risk of cardiovascular death, myocardial infarction and stroke when used with aspirin in patients presenting with ACS. - Myocardial infarction prevention: lowers incidence of recurrent MI and cardiovascular events in patients with a prior MI. - Post‑percutaneous coronary intervention (PCI) antiplatelet therapy: provides sustained platelet inhibition to prevent stent thrombosis after PCI, typically as part of dual antiplatelet therapy.

Ticagrelor may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dyspnea: shortness of breath or breathing difficulty. - Headache: mild to moderate head pain. - Nausea: feeling of stomach upset. - Diarrhea: loose stools. - Bruising: increased tendency to bruise. - Elevated serum uric acid: mild increase in uric acid levels.

Serious or Rare Side Effects: - Severe bleeding: life‑threatening hemorrhage including intracranial or gastrointestinal. - Thrombotic thrombocytopenic purpura (TTP): rare immune‑mediated disorder. - Hypersensitivity reactions: rash, angioedema or anaphylaxis. - Hepatotoxicity: significant liver enzyme elevation. - Bradyarrhythmias: marked slowing of heart rate. - Cardiogenic shock: rare severe cardiac dysfunction.

When prescribing Ticagrelor, clinicians should consider several precautionary measures to ensure safe use. - Assess bleeding risk: evaluate history of hemorrhage, recent surgery or trauma. - Monitor renal function: adjust therapy in patients with severe renal impairment. - Check hepatic status: use caution in moderate to severe liver disease. - Concomitant antithrombotics: avoid unnecessary combination with other anticoagulants. - Pregnancy and lactation: weigh benefits against potential risks; limited data available. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Ticagrelor can interact with other medicines, altering its antiplatelet effect or increasing adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor plasma levels and bleeding risk. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy, increasing thrombotic risk.

Moderate Interactions (Monitor Closely): - Aspirin: combined use heightens bleeding potential; monitor for signs of hemorrhage. - NSAIDs (e.g., ibuprofen, naproxen): may increase gastrointestinal bleeding risk. - Anticoagulants (e.g., warfarin, DOACs): additive anticoagulant effect requires careful monitoring. - Statins metabolized by CYP3A4 (e.g., atorvastatin): may raise statin concentrations; observe for myopathy.